So here we are again.
Last year, a Congressional panel met to discuss consumer genetic testing. Some of the speakers issued statements that were so factually inaccurate as to be offensive; then, they largely concluded that people should be protected from their own curiosity. This week, an FDA panel met to discuss consumer genetic testing. Some of the speakers issued statements that were factually inaccurate and in one case plain offensive; then, they largely concluded that people should be protected from their own curiosity.
When I wrote a six-part series about consumer genetic testing last year for Newsweek, I was not an advocate on either side. (At least I didn’t start out that way.) Now I find myself squarely in one camp and sorely disappointed in the way the dialogue on the issue has played out over the last few months. What motivated me to write about the issue in the first place was a feeling that consumers were being left out of a debate that was supposed to be about them. Critics in Congress and the GAO were concerned that people would mistakenly treat their necessarily incomplete genetic data sets as crystal balls, but how many customers were actually invited to the Congressional hearing to share how they might think about their results? None. This time around, at the public meeting, how many consumers were expressly invited to speak? None. It’s hard to see how people in power could ever look fairly at consumer genetic testing, given that every time they tackle the issue they end up having the same conversation without bothering to get direct input from the people whose welfare they’re purporting to protect. UPDATE: After the meeting, the FDA held an official public comment period. This was a great way to to get consumer input, and the agency should be commended for it.
So here I am again, waving my hands and jumping up and down, trying to provide some of that input.
